Prospective Analysis of Arteriovenous Access (AVA) Use for Continuous Renal Replacement Therapy (… (NCT07447128) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
Prospective Analysis of Arteriovenous Access (AVA) Use for Continuous Renal Replacement Therapy (CRRT)
United States50 participantsStarted 2026-03
Plain-language summary
Arteriovenous fistula or graft are the ideal hemodialysis access. Nonetheless the most common access type used for Continuous Renal Replacement Therapy (CRRT) is either a temporary or permanent hemodialysis catheter. Recommendations for the use of catheters to deliver CRRT in end stage kidney disease (ESKD) patients are lacking on data and subjective to anecdotal experiences and expert consensus. The repetitive placement of catheters in ESKD patients have shown to increase the chances of central vascular stenosis which is one of the main risk factors that lead to access failure. Also, the repetitive use of dialysis catheters increases the risk for catheter associated infections. Dedicated studies demonstrating the safety and feasibility of using arteriovenous access (AVA) for CRRT are scarce. No screening criteria or algorithm exists to determine the adequate patient and clinical scenario to use AVA for CRRT.
Goals of the study:
1. To develop a standard operating procedure for the use of AVA in CRRT.
2. Evaluate the safety and efficacy of using AVA for CRRT.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Age 18 years or older
* Diagnosis of End-Stage Kidney Disease (ESKD) receiving maintenance chronic hemodialysis
* Admission to the Intensive Care Unit (ICU)
* Presence of a functioning arteriovenous fistula (AVF) or arteriovenous graft (AVG)
* Clinical indication for Continuous Renal Replacement Therapy (CRRT)
* Score of ≥16 points on the study enrollment screening tool
Exclusion Criteria:
* Age under 18 years
* Arteriovenous access thrombectomy within 30 days prior to study enrollment
* Documented prolonged bleeding from arteriovenous access within 30 days prior to study enrollment
* Current dialysis via temporary or tunneled hemodialysis catheter
* International Normalized Ratio (INR) \> 3.0
* Acute liver failure, defined as AST \> 1000 U/L and/or ALT \> 1000 U/L
* Platelet count \< 50,000/µL
* Evidence of disseminated intravascular coagulation (DIC)
* Pregnant patients
* Patients actively attempting to become pregnant
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1This trial is looking at how well arteriovenous access holds up during continuous renal replacement therapy — can you explain how AV access is different from the standard venous catheters typically used for CRRT, and whether that difference matters for my situation?
2Since this study isn't recruiting yet, how long do you think it might be before it opens, and is there a reason to wait for it rather than moving forward with a treatment plan now?
3The trial is observational and measuring 'access survival' — does that mean patients aren't being assigned to a new treatment, and if so, what would my actual care look like if I were eventually enrolled?
4Given that this is listed as phase 'not applicable,' what does that tell us about the level of evidence behind AV access for CRRT, and are there already published studies you'd want me to review before considering this?
5For someone with end-stage kidney disease who may need ongoing renal replacement therapy, would participating in a study like this conflict with or delay any other treatment options — like preparing for long-term dialysis or a kidney transplant evaluation?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Access survival
Timeframe: From initiation of CRRT until discontinuation of CRRT, occurrence of access failure (defined as thrombosis, major access-related complication, or need for temporary dialysis catheter placement), ICU discharge, or up to 30 days after CRRT initiation.